JNJ shares slide slightly with resistance looming at $231.70: weekly review
Johnson & Johnson (JNJ) is currently trading at $224.73, having declined by $2.56 (0.98%) over the last week and closing near the bottom of its recent weekly range. The asset remains below the weekly MA-20 ($230.73), signaling some short-term selling pressure, but continues to hold well above its MA-50 ($199.59) and MA-200 ($169.71), indicating robust longer-term support.
258.57
258.57
Highlights
- Johnson & Johnson faces near-term selling pressure, trading below short-term moving averages despite maintaining a longer-term bullish structure.
- Momentum signals are mixed, with bullish MACD and ADX offset by overbought oscillators and growing seller dominance.
- The expected seven-day range is $219.00–$231.70, with a 75% probability of an upside move if resistance near $231.70 breaks.
Bullish momentum over the week despite oscillators signaling oversold
Technical analysis on the weekly (W1) timeframe shows mixed conditions for JNJ. The weekly MACD and ADX are solidly bullish, underlining strong underlying positive momentum. However, several oscillators indicate oversold levels, including the Stochastic RSI, while the weekly RSI remains in buy territory. Bull/Bear Power on the weekly chart points to pronounced seller dominance, all within a weekly volatility of 3.39%. Key nearby levels are support at $219.00 and resistance at $231.70.
Upward bias next week as bullish momentum faces pivotal resistance
Looking ahead to the next five trading days, JNJ is expected to fluctuate within a range of $219.00 – $231.70, reflecting current weekly volatility. There is about a 75% probability of an upward move as three out of four weekly momentum indicators remain in Buy or Strong Buy territory, although mild divergence exists between trend-following and mean-reversion signals. Baseline expectations are for sideways action within the defined corridor, with a possible breakout to the upside if weekly resistance at $231.70 is surpassed, or a move lower if support around $219.00 is breached.
Previously it was reported that bipartisan lawmakers urged the U.S. State Department to release appropriated funds to support global vaccine distribution through Gavi, a key international health partnership. While this underscores ongoing public sector backing for large vaccine producers like Johnson & Johnson, traders should closely monitor shifts in policy sentiment as a potential catalyst for volatility beyond current technical signals.
Latest Johnson & Johnson News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
